Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445298 | 0.84 | AKR1A1 (0.51) | STAT3ALDH1A1 | |
| SCHEMBL28247078 | 0.84 | PRMT5 (0.48) | STAT3ALDH1A1TBXAS1KMT2AMAPT | |
| SCHEMBL1520240 | 0.83 | TBXAS1 (0.64) | STAT3ALDH1A1TBXAS1KMT2AKDM4E | |
| SCHEMBL12874520 | 0.81 | KMT2A (0.66) | STAT3ALDH1A1TBXAS1KMT2AKDM4E | |
| SCHEMBL18180209 | 0.81 | CDC25A (0.63) | STAT3ALDH1A1TBXAS1KMT2AKDM4E | |
| SCHEMBL419619 | 0.81 | MAPT (0.70) | ALDH1A1KMT2AKDM4EMAPTMEN1 | |
| SCHEMBL443715 | 0.81 | KRAS (0.59) | STAT3ALDH1A1TBXAS1PTGDR2GAA | |
| SCHEMBL6567317 | 0.80 | ALDH1A1 (0.58) | STAT3ALDH1A1TBXAS1KMT2AKDM4E | |
| SCHEMBL8021536 | 0.79 | MCL1 (0.60) | STAT3ALDH1A1TBXAS1KMT2AKDM4E | |
| SCHEMBL9701519 | 0.79 | KMT2A (0.60) | STAT3ALDH1A1TBXAS1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270912-A1 | Substituted Indolealkanoic Acids | JONES MICHAEL LEE (US) | 2012-10-25 | — | — | US | disclosed |
| US-8163932-B2 | Substituted indolealkanoic acids | ALINEA PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120065203-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2012-03-15 | — | — | US | disclosed |
| US-20100324105-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100324039-A1 | Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100137301-A1 | Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2010-06-03 | — | — | US | disclosed |
| US-7659269-B2 | Substituted indolealkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2010-02-09 | — | — | US | disclosed |
| US-20080214540-A1 | 3-[(phenyl or benzothiazol-2-yl)methyl]indole-N-acetic acids and esters; analgesics; aldose reductase inhibitors; diabetes complications including cataracts, retinopathy, nephropathy, and neuropathy; side effect reduction | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2008-09-04 | — | — | US | disclosed |
| US-7304079-B2 | Preparing 3-benzothiazolylalkyl-1-indolylacetic acids and esters by cyclizing a 3-(anilinothiocarbonylalkyl)-1-indolylacetic ester with potassium ferricyanide or sodium hydride, optionally deprotecting the acid group; aldose reductase inhibitors for diabetic complications; side effect reduction | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1539175-A4 | SUBSTITUTED INDOLEALKANOIC ACIDS DERIVATIVE AND FORMULATIONS CONTAINING SAME FOR USE IN TREATMENT OF DIABETIC COMPLICATIONS | INST FOR PHARM DISCOVERY INC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-6521659-B2 | 3-(4,5,7-trifluorobenzothiazol-2-yl) methyl-indole-N-acetic acid, ethyl ester and benazepril, for example; reduces serum glucose and triglycerides; treating angiogenesis, hyperglycemia, hyperlipidemia and diabetes mellitus | INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2003-02-18 | — | — | US | disclosed |
| US-20030018053-A1 | Substituted indolealkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC. | 2003-01-23 | — | — | US | disclosed |
| US-6426344-B2 | INDOLEALKANOIC ACID DERIVATIVES INHIBITS ALDOSE REDUCTASE AND USEFUL FOR TREATING CHRONIC COMPLICATION ASSOCIATED WITH DIABETES MELLITUS INCLUDING DIABETIC CATARACTS, RETINOPATHY, NEPHROPATHY AND NEUROPATHY | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC | 2002-07-30 | — | — | US | disclosed |
| US-20010044437-A1 | Methods for reducing uric acid levels | INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC, THE | 2001-11-22 | — | — | US | disclosed |
| US-20010041722-A1 | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor | ALINEA PHARMACEUTICALS, INC. | 2001-11-15 | — | — | US | disclosed |
| US-20010016661-A1 | Substituted indolealkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY | 2001-08-23 | — | — | US | disclosed |
| WO-2001051489-A2 | METHODS FOR LOWERING URIC ACID LEVELS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-07-19 | — | — | WO | disclosed |
| US-6214991-B1 | 3-(4,5,7-TRIFLUOROBENZOTHIAZOL-2-YL)METHYL-INDOLE-N-ACETIC ACID, ETHYL ESTER FOR EXAMPLE; TREATING COMPLICATIONS OF DIABETES MELLITUS, SUCH AS CATARACTS, RETINOPATHY, NEPHROPATHY, AND NEUROPATHY | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. | 2001-04-10 | — | — | US | disclosed |
| EP-1066283-A2 | SUBSTITUTED INDOLEALKANOIC ACIDS | The Institutes for Pharmaceutical Discovery, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999050268-A2 | SUBSTITUTED INDOLEALKANOIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016661-A1 | Substituted indolealkanoic acids | GPR119, AANAT, AADAT | STAT3 2951/4885ALDH1A1 338/4885TBXAS1 571/4885 |
| US-20120065203-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | LIPG, PNLIP, LIPA | STAT3 1635/4885ALDH1A1 513/4885TBXAS1 148/4885 |
| US-20100324039-A1 | Substituted Indolealkanoic Acids | GPR119, AANAT, AADAT | STAT3 2951/4885ALDH1A1 338/4885TBXAS1 571/4885 |
| US-20030018053-A1 | Substituted indolealkanoic acids | GPR119, AANAT, AADAT | STAT3 2951/4885ALDH1A1 338/4885TBXAS1 571/4885 |
| US-20100324105-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | LIPG, PNLIP, LIPA | STAT3 1635/4885ALDH1A1 513/4885TBXAS1 148/4885 |
| US-20010044437-A1 | Methods for reducing uric acid levels | XDH, LIPA, OAT | STAT3 4151/4885ALDH1A1 149/4885TBXAS1 1665/4885 |
| US-20010041722-A1 | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor | AGT, LIPG, ACE | STAT3 2428/4885ALDH1A1 288/4885TBXAS1 491/4885 |
| US-20100137301-A1 | Substituted Indolealkanoic Acids | GPR119, AANAT, AADAT | STAT3 2951/4885ALDH1A1 338/4885TBXAS1 571/4885 |
| US-20120270912-A1 | Substituted Indolealkanoic Acids | GPR119, AANAT, AADAT | STAT3 2951/4885ALDH1A1 338/4885TBXAS1 571/4885 |
| US-20080214540-A1 | 3-[(phenyl or benzothiazol-2-yl)methyl]indole-N-acetic acids and esters; analgesics; aldose reductase inhibitors; diabetes complications including cataracts, retinopathy, nephropathy, and neuropathy; side effect reduction | AKR1C3, AKR1C2, AKR1B1 | STAT3 4268/4885ALDH1A1 31/4885TBXAS1 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.